Company Overview and News

Blackham Resources delivers strong production growth and reaffirms June half year guidance

Blackham Resources Ltd (ASX:BLK) has delivered quarter-on-quarter production growth of 38% for the March quarter at its Matilda-Wiluna gold operation in Western Australia.
Upvote Downvote

Blackham Resources continues step-change with record gold production and reduced costs

Blackham Resources Ltd (ASX:BLK) remains on track with its turnaround after achieving record gold production during the March quarter at significantly reduced costs.
Upvote Downvote

Blackham targeting extension plan for Golden Age mine in WA

Blackham Resources has announced a mine plan extension for its Golden Age underground gold mine, which has been extended six months to the end of December. Golden Age is a high-grade, free-milling quartz vein gold mine located not far from Blackham’s Wiluna operation, 750km northeast of Perth, Western Australia.
Upvote Downvote

Blackham Resources extends production at Golden Age and seeks to extend mine plan

Blackham Resources Ltd’s (ASX:BLK) Golden Age underground gold mine plan continues to grow with it being extended for a further 6 months to December 2018.
Upvote Downvote

Blackham Resources does deal to evaluate nearby potash potential

Blackham Resources Ltd (ASX:BLK) has entered a memorandum of understanding (MoU) with Salt Lake Potash (ASX:SO4) to investigate a sulphate of potash opportunity.
Upvote Downvote

Blackham Resources generates strong February gold production, continues turnaround

Blackham Resources Ltd (ASX:BLK) has had more than its fair share of twists and turns since being one of the best performing microcap gold stocks in the first half of 2016 with its shares increasing five-fold to a high of 81 cents.
Upvote Downvote

Bard1 Life Sciences is one of the ASX’s most active top performers today

Bard1 Life Sciences Ltd (ASX:BD1) is one of the most actively traded stocks on the ASX today with over 88 million shares changing hands around 2.00pm AEST.
Upvote Downvote

Blackham Resources surges 40% as output increases and costs fall

Blackham Resources Limited (ASX:BLK) surged after a record month for its Matilda-Wiluna gold operation - one in which output increased and costs were significantly reduced, resulting in strong cash flows.
Upvote Downvote

Blackham Resources enjoys record month as output increases and costs fall

Blackham Resources Limited (ASX:BLK) said February was a record month for its Matilda-Wiluna gold operation - one in which output increased and costs were significantly reduced, resulting in strong cash flows.
Upvote Downvote

Blackham Resources has a new substantial shareholder

Blackham Resources Ltd (ASX:BLK) has a new sUBStantial shareholder in Regal Funds Management Pty Limited, which holds an interest of 5.19%.
Upvote Downvote

Blackham Resources settles $35.9 million and appoints ex ASX 200 CFO to board

Blackham Resource Ltd (ASX:BLK) has now settled the rights issue which raised $35.9 million in funding through the issue of 897.6 million shares and 448.8 million options.
Upvote Downvote

Blackham Resources offer strongly supported, raises $31.16 million

Blackham Resources Ltd (ASX:BLK) received a strong level of acceptances for its fully underwritten, renounceable pro-rata entitlement offer, raising $31.16 million.
Upvote Downvote

Blackham finalises $36m raising

Gold miner Blackham Resources has completed a $36 million entitlement issue with help from underwriters, as the company looks to cut debt.
Upvote Downvote

Blackham Resources surges 30% after record monthly gold production at low costs

Blackham Resources Ltd (ASX:BLK) has provided a promising update for the month of January in relation to its Matilda-Wiluna Gold Operation located in Western Australia.
Upvote Downvote

Blackham Resources posts record production at Matilda-Wiluna project

Perth-based explorer Blackham Resources, responsible for the Matilda-Wiluna gold operation in Western Australia, has announced a record production month for January, producing 6490 ounces (oz) of gold.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...